Nimedine (Cilastatin, Imipenem)

Imipenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, leading to cell lysis. Cilastatin is co‑administered to inhibit renal dehydropeptidase I, an enzyme that would otherwise degrade imipenem, thereby preserving its plasma concentration and antibacterial activity.

The dose of Nimedine is determined by the prescribing clinician based on the type and severity of infection, the patient’s renal function, body weight, and other clinical factors. No fixed regimen is provided here; the prescriber sets the appropriate dosing schedule.

Safety data for imipenem/cilastatin in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To order Nimedine, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where applicable) and import documentation.

Both Nimedine (imipenem/cilastatin) and meropenem belong to the carbapenem class and provide broad‑spectrum coverage against Gram‑negative, Gram‑positive and anaerobic bacteria. Imipenem is often combined with cilastatin to protect it from renal degradation, whereas meropenem is administered without a renal inhibitor. Choice between them depends on local resistance patterns, pharmacokinetic considerations and clinician preference.

Nimedine should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Prior to use, the solution should be inspected for particulate matter and discoloration, and prepared according to aseptic technique.

Nimedine is given as an intravenous infusion. The reconstituted solution is administered over a short period, typically 30 minutes, under the supervision of qualified healthcare personnel. Infusion rate and duration are adjusted according to the patient’s clinical status and renal function.

The most serious adverse reactions include seizures, especially in patients with renal impairment or pre‑existing CNS disorders; severe hypersensitivity reactions such as anaphylaxis; Clostridioides difficile‑associated colitis; and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Nimedine is contraindicated in patients with a known hypersensitivity to imipenem, cilastatin, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for patients with a history of seizures, severe renal impairment, or those receiving valproic acid, due to potential drug‑interaction risks.